AbbVie plays its ace cards against Humira's decline

A powerful anti-inflammatory medication and tumor necrosis factor-alpha blocker, Humira is approved as a treatment for patients with rheumatoid arthritis, Crohns disease and other autoimmune diseases characterized by dysregulated immune responses and inflammation. Amjevitas head start Oddly, the company that was considered to be in the best position to challenge Humiras dominance did not capture market share that was anywhere near proportional to Humiras sales decline. In a statement to shareholders, Amgen explained that sales picked up in the fourth quarter of 2023, climbing 43% quarter over quarter, because of higher inventory and higher net selling price, partly offset by volume decline.